USV Limited, leaders in the anti-diabetic drug segment in India, announced that the company’s new facility at Baddi to produce oral solids (tablets) for anti diabetic and cardio-vascular therapies has commenced operations. Built at an investment of Rs.80 crore, this facility has manufacturing capacity for 2.5 billion tablets in a year. Spread over 3 acres, the plant is built to meet USFDA standards and is environment friendly. It adheres to global safety standards and is ISO 14001 (environment management systems) and OHSAS 18001 (occupational health and safety) certified and GMP compliant.
Lifestyle therapeutic segment includes diabetes, cardiovascular and gastro-intestinal medications. According to IMS, the segment recorded growth of 22% in the year 2010 and is likely to exceed this figure in the current year. For over two decades, USV leads the anti-diabetic drug segment in India, both in prescription and value. In the cardio-vascular drug segment, the company leads in prescription and is amongst the top ten in value.
Commenting on the occasion, Prashant Tewari, managing director, USV Limited said, “The increasing reach of modern medicines in our country, even in the hinterlands, and people’s access to modern medical care to improve their lives presents an opportunity and challenge for us. The market is expanding and manufacturing capabilities have to keep pace. This new facility at Baddi will mark another milestone for USV’s growth and success in our endeavour to be reliable healthcare partners.”
USV’s two other manufacturing facilities at Chiplun (Maharashtra) and Daman are USFDA approved facilities. USV is amongst the few Indian companies with a USFDA approved sterile injectible facility. The new Baddi facility will boost the company’s manufacturing capability to address the growing market needs, both in India and internationally. 68 per cent of USV’s annual revenue are derived from the domestic market while international business contributes around 32 per cent.
The over Rs.1000 crore Mumbai based USV Limited is the largest manufacturer of Metformin, an anti-diabetic drug, in the world. In the Indian market, the company is the leading player in the anti-diabetic drug segment both in prescription and value. It is also amongst the leading players in the cardio-vascular drug segment.
On the research front, USV is engaged in research in the areas of rDNA proteins and peptides. USV has an IP Portfolio of patents in areas of drug delivery, chemistry and biotechnology.